PMID- 25643195
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20220408
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 16
IP  - 6
DP  - 2015 Jun
TI  - The prognostic value of circulating microRNAs in heart failure: preliminary 
      results from a genome-wide expression study.
PG  - 431-7
LID - 10.2459/JCM.0000000000000233 [doi]
AB  - INTRODUCTION: Recent studies have demonstrated the potential of microRNAs (miRNA) 
      as biomarkers in various cardiovascular disorders. The aim of the present study 
      was to quantitatively evaluate the expression levels of miRNAs in patients with 
      chronic congestive heart failure (CHF) in order to identify differential 
      expression profiles as biomarkers with prognostic values. MATERIALS AND METHOD: 
      The study included 20 clinically stable [New York Heart Association (NYHA) II] 
      and 22 decompensated (NYHA III and IV) CHF patients and 15 healthy controls. 
      miRNA profiling was performed using a microarray method. Dysregulated miRNAs were 
      evaluated for their biomarker potential. RESULTS: Microarray profiling revealed 
      an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, 
      miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 
      miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, 
      miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, 
      miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients. The prognostic 
      value of miR-182 [area under the curve (AUC) 0.695] was found to be superior to 
      pro-brain type natriuretic peptide (NT-proBNP; AUC 0.350) and high-sensitivity 
      C-reactive protein (hs-CRP) (AUC 0.475) by receiver operator characteristic (ROC) 
      analysis. Cox regression analysis showed that miR-182 could predict 
      cardiovascular mortality (P = 0.032). CONCLUSION: We demonstrated the increased 
      expression levels of circulating miRNAs in CHF as compared with controls. 
      Moreover, miR-182 was found to be a potential prognostic marker in CHF.
FAU - Cakmak, Huseyin Altug
AU  - Cakmak HA
AD  - aRize Kackar Government Hospital, Department of Cardiology, Rize bIstanbul 
      University, Faculty of Medicine, Department of Internal Medicine, Division of 
      Medical Genetics, Istanbul cIstanbul University, Cerrahpasa Faculty of Medicine, 
      Department of Cardiology, Istanbul dIstanbul University, Institute of 
      Experimental Medicine, Department of Molecular Medicine, Istanbul, Turkey.
FAU - Coskunpinar, Ender
AU  - Coskunpinar E
FAU - Ikitimur, Baris
AU  - Ikitimur B
FAU - Barman, Hasan Ali
AU  - Barman HA
FAU - Karadag, Bilgehan
AU  - Karadag B
FAU - Tiryakioglu, Necip Ozan
AU  - Tiryakioglu NO
FAU - Kahraman, Kadriye
AU  - Kahraman K
FAU - Vural, Vural Ali
AU  - Vural VA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Biomarkers)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn182 microRNA, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation
MH  - Genome-Wide Association Study/methods
MH  - Heart Failure/*diagnosis/genetics
MH  - Humans
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Prognosis
MH  - Prospective Studies
EDAT- 2015/02/03 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/02/03 06:00
PHST- 2015/02/03 06:00 [entrez]
PHST- 2015/02/03 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
AID - 10.2459/JCM.0000000000000233 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2015 Jun;16(6):431-7. doi: 
      10.2459/JCM.0000000000000233.